These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1862551)

  • 21. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
    Razis E; Dimopoulos AM; Bafaloukos D; Papadimitriou C; Kalogera-Fountzila A; Kalofonos H; Briassoulis E; Samantas E; Keramopoulos A; Pavlidis N; Kosmidis P; Fountzilas G
    Cancer Invest; 2001; 19(2):137-44. PubMed ID: 11296618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Phase II study of epirubicin on breast cancer: a cooperative group study].
    Tominaga T; Kitamura M; Nomura Y; Abe O; Enomoto K; Ikeda T; Izuo M; Iino Y; Taguchi T; Tamura K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2187-92. PubMed ID: 3459397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
    Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
    Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly epirubicin in advanced breast cancer.
    Tucci E; Algeri R; Guarnieri A; Pepi F; Sapio L; Bastreghi G; Pirtoli L
    Tumori; 1988 Dec; 74(6):689-92. PubMed ID: 3232214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papadimitriou C; Dafni U; Bafaloukos D; Skarlos D; Moulopoulos LA; Razis E; Kalofonos HP; Aravantinos G; Briassoulis E; Papakostas P; Abela K; Gogas E; Kosmidis P; Pavlidis N; Dimopoulos MA
    J Clin Oncol; 2001 Apr; 19(8):2232-9. PubMed ID: 11304776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
    Brufman G; Colajori E; Ghilezan N; Lassus M; Martoni A; Perevodchikova N; Tosello C; Viaro D; Zielinski C
    Ann Oncol; 1997 Feb; 8(2):155-62. PubMed ID: 9093724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
    Kouroussis C; Xydakis E; Potamianou A; Giannakakis T; Kakolyris S; Agelaki S; Sara E; Malamos N; Alexopoulos A; Mavroudis D; Samonis G; Papadouris S; Georgoulias V; Panagos G
    Ann Oncol; 1999 May; 10(5):547-52. PubMed ID: 10416004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
    Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
    Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II study of epirubicin on gastric cancer--a cooperative study of the Tokai Cancer Chemotherapy Group].
    Kimura K; Suga S; Kano H; Sakakibara K; Hayashi T; Nakai T; Nagano I; Yokoyama Y; Morise K; Hayakawa M
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2440-5. PubMed ID: 3460530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
    Esteban E; Modollel A; González de Sande L; Palacio I; Muñiz I; Fernández Y; Corral N; Fra J; Sala M; Vieitez JM; Estrada E; Lacave AJ;
    Breast Cancer Res Treat; 2003 Aug; 80(3):257-65. PubMed ID: 14503798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
    Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
    Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3277-81. PubMed ID: 3143311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group.
    Jassem J; Karnicka-Młodkowska H; Drozd-Lula M; Strug A; Pilarska-Machowicz A; Michalski A; Kowal E; Moś-Antkowiak R; Zych J
    Eur J Cancer; 1992; 28(2-3):473-6. PubMed ID: 1317199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer.
    Fountzilas G; Skarlos D; Giannakakis T; Athanasiades A; Bafaloukos D; Kalogera-Fountzila A; Bamia C; Pavlidis N; Kosmidis P
    Eur J Cancer; 1994; 30A(7):965-9. PubMed ID: 7524579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
    Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
    Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
    Langenbuch T; Mross K; Jonat W; Hossfeld DK
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.